All Drug Glassy Microneedle Patches for Instantaneous Transdermal Delivery

Dissolving microneedles (DMNs) are emerging transdermal delivery platforms but rely on water‐soluble polymers as carriers that inherently limit drug‐loading capacity and slow release due to dissolution/diffusion barriers. Formulating drugs directly into robust DMNs is further challenged by crystallization tendencies. Here, a supramolecular engineering strategy enabling carrier‐free antibiotic glass microneedles (GMNs) is presented, leveraging synergistic drug‐sulfate‐water interactions that suppress crystallization and form mechanically stable amorphous networks. Using tobramycin sulfate, monolithic GMNs are achieved with 100%‐drug payload, exceptional strength (Young's modulus 5.1 GPa), and instant transdermal delivery (threefold faster than polymer DMNs). Eliminating polymeric carriers accelerates drug diffusion by 2.6‐fold, enabling deep tissue penetration for efficient biofilm eradication. In vivo evaluation demonstrates that the antibiotic GMNs effectively promote the healing of biofilm‐infected skin wounds in mice and exhibit potent therapeutic efficacy against subcutaneous abscesses. This strategy extends broadly to aminoglycoside antibiotics. By replacing the polymer matrix with supramolecular‐engineered amorphous networks, a next‐generation DMN platform is pioneered that bridges critical gaps in drug‐loading efficiency, dissolution kinetics, and clinical translation for urgent therapeutic applications.